Format

Send to:

Choose Destination
See comment in PubMed Commons below
Br J Cancer. 2012 Sep 25;107(7):1009-16. doi: 10.1038/bjc.2012.399. Epub 2012 Sep 4.

Biomarkers: the next therapeutic hurdle in metastatic renal cell carcinoma.

Author information

  • 1Urologic Medical Oncology, University of Alabama at Birmingham (UAB) Comprehensive Cancer Center, Birmingham, AL 35294, USA.

Abstract

Despite recent advances, metastatic renal cell carcinoma remains largely an incurable disease. Vascular endothelial growth factor and mammalian target of rapamycin inhibitors have provided improvements in clinical outcomes. High-dose interleukin 2 remains an option for highly selected patients and is associated with durable remissions in a small minority of patients. The toxicity profiles of specific agents and patient characteristics and comorbidities and costs have an important role in the current choice of therapy. Major challenges encountered in developing molecular biomarkers to guide therapy are tumour heterogeneity and standardisation of tissue collection and analysis. Although biomarkers are in their infancy of development, they should be a priority in early preclinical and clinical development in order to guide rational tailored development of emerging agents.

PMID:
22948724
[PubMed - indexed for MEDLINE]
PMCID:
PMC3461173
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Nature Publishing Group Icon for PubMed Central
    Loading ...
    Write to the Help Desk